ANTIBODIES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS

InBio LtdInBio Ltd..______________________________________________________________________

Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826

InBio LtdInBio Ltd..

ANTIBODIES FOR THERAPEUTIC AND

DIAGNOSTIC APPLICATIONS



Facts on InBio

• Established in Tallinn, 1999

• General business idea: to develop new effective and selective skin cancer therapeutics and diagnostics.

• The company was initiated by a group of scientists of National Institute of Chemical Physics and Biophysics and Karolinska Institute, Sweden



1999 2000 2001Turnover 10000 225000 190000

Profit before taxes

-2000 19000 8000

Equity 3300 3300 3300Employees 2 4 7

Financial results (EUR):



Background for product development

• Cancer is the second most common cause of death in the developed world

• The limits of usefulness are being approached for conventional therapies and further advances will require principally new approaches

• The foreseen products of our company are prototypes of new anti-cancer drugs that are characterised by:

– -high degree of selectivity – -efficient delivery



What is antibody?

• Antibodies are made by a class of white blood cells

• They are naturally present in the blood

• Biological function is to perform defence functions

• Each antigen causes the formation of a specific antibody

• Recombinant DNA technology allows the engineer antibodies

• It is possible to produce complete antibodies in cell culture systems.



Reasons to use antibodies in drug development

• Can be rationally designed and easily made

• Can be engineered to add fragmenmts that enhance their therapeutic potential

• Have no intrinsic toxicity as based on the natural molecules

• Monoclonal antibodies (mAbs)will not fail at the drug safety testing (phase I clinical trial stages)

• Technology is now advanced enough for therapeutic applications of mAbs



What is new in our technology?

• Our technology combines two different platforms:

• Monoclonal antibodies against cancer-specific antigens

– Modification of antibody sequence to make these mAbs membrane permeable

• Such approach helps to utilise intracellular cancer-specific targets that can not be usually reached

• Focus on skin cancer, first targets are GLI proteins



What are GLI proteins?

• GLI proteins are gene switches

• GLI proteins are involved in development and lead cells to divide

• Abnormal activation of GLI proteins lead to cancer

• GLI proteins represent an attractive target for anticancer drug development



Gene switch turned on Cancer develops

Cancer development inhibited



Cell penetrating peptides (CPPs)

• Family of peptides capable to penetrate cellular membranes

• We can transport the following molecules into cells using CPP technology:

• -other peptides

• -nucleic acids

• -proteins e.g. antibodies



World antibody market:

• Currently more than 200 monoclonal antibodies are in development

• Targeted disorders include cancer, heart disease, infectious diseases and autoimmune diseases

• Market is still in its inception stage,

• Market size estimated at nearly $2.8 billion in 1999,



World antibody market:

• Market forecast growth to almost $9.8 billion in 2004.

• Expected therapeutic antibody average annual growth rate is projected at 21,8%

• Diagnostic/therapeutic antibody AAGR will grow at fast nearly 50% rate

• Main Target Markets for InBio:

• Scandinavian Market

• U.S. market



Timing and positioning

• Antibody based drugs are in the position of significant commercial growth

• InBio enters the market at the moment when all developers seek for new approaches

• InBio has new technology to make antibodies more effective

• InBio has involved outstanding specialists from all fields that are required to accomplish our business plan



Benefits for the investor:

• Will invest in profitable business at evolving market

• Will invest in area that is significantly improving the well-being of the mankind

• Will get possession rights of a unique know-how and new technologies that will realise in new type of therapeutic and diagnostic tools

ANTIBODIES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS

Documents

Transcript of ANTIBODIES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS